Acute Urinary Retention Rates in the General Male Population and in Adult Men With Lower Urinary Tract Symptoms Participating in Pharmacotherapy Trials: A Literature Review

Oelke, Matthias; Speakman, Mark; Desgrandchamps, François; Mamoulakis, Charalampos

doi:10.1016/j.urology.2015.06.025

Cited by 31 publications

(35 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, the exact definitions of AUR and CUR remain controversial [3]. The exact incidence of UR in the general population remains unclear, with various estimates suggested from 2.2 to 6.8 events/1000 patientyears [4,5]. Benign prostatic obstruction (BPO) is considered the most prevalent cause of UR in men [5].…”

Section: Introductionmentioning

confidence: 99%

Management of Urinary Retention in Patients with Benign Prostatic Obstruction: A Systematic Review and Meta-analysis

et al. 2019

Self Cite

View full text Add to dashboard Cite

Context: Practice patterns for the management of urinary retention (UR) secondary to benign prostatic obstruction (BPO; UR/BPO) vary widely and remain unstandardized. Objective: To review the evidence for managing patients with UR/BPO with pharmacological and nonpharmacological treatments included in the European Association of Urology guidelines on non-neurogenic male lower urinary tract symptoms. Evidence acquisition: Search was conducted up to April 22, 2018, using CENTRAL, MEDLINE, Embase, ClinicalTrials.gov, and World Health Organization International Clinical Trials Registry Platform. This systematic review included randomized controlled trials (RCTs) and prospective comparative studies. Methods as detailed in the Cochrane handbook were followed. Certainty of evidence (CoE) was assessed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. Evidence synthesis: Literature search identified 2074 citations. Twenty-one studies were included (qualitative synthesis). The evidence for managing patients with UR/ BPO with pharmacological or nonpharmacological treatments is limited. CoE for most outcomes was low/very low. Only a1-blockers (alfuzosin and tamsulosin) have been evaluated in more than one RCT. Pooled results indicated that a1-blockers provided

show abstract

Section: Introductionmentioning

confidence: 99%

Management of Urinary Retention in Patients with Benign Prostatic Obstruction: A Systematic Review and Meta-analysis

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 99%

Management of urinary retention in patients with benign prostatic obstruction: A systematic review and meta-analysis

Karavitakis¹,

Kyriazis²,

Omar³

et al. 2019

European Urology Supplements

View full text Add to dashboard Cite

E U R O P E A N U R O L O G Y X X X ( 2 0 1 8 ) X X X -X X X a v a i l a b l e a t w w w . s c i e n c e d i r e c t . c o m j o u r n a l h o m e p a g e : w w w . e u r o p e a n u r o l o g y . c o m AbstractContext: Practice patterns for the management of urinary retention (UR) secondary to benign prostatic obstruction (BPO; UR/BPO) vary widely and remain unstandardized. Objective: To review the evidence for managing patients with UR/BPO with pharmacological and nonpharmacological treatments included in the European Association of Urology guidelines on non-neurogenic male lower urinary tract symptoms. Evidence acquisition: Search was conducted up to April 22, 2018, using CENTRAL, MEDLINE, Embase, ClinicalTrials.gov, and World Health Organization International Clinical Trials Registry Platform. This systematic review included randomized controlled trials (RCTs) and prospective comparative studies. Methods as detailed in the Cochrane handbook were followed. Certainty of evidence (CoE) was assessed using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach. Evidence synthesis: Literature search identified 2074 citations. Twenty-one studies were included (qualitative synthesis). The evidence for managing patients with UR/ BPO with pharmacological or nonpharmacological treatments is limited. CoE for most outcomes was low/very low. Only a1-blockers (alfuzosin and tamsulosin) have been evaluated in more than one RCT. Pooled results indicated that a1-blockers provided significantly higher rates of successful trial without catheter compared with placebo [alfuzosin: 322/540 (60%) vs 156/400 (39%) (odds ratio {OR} 2.28, 95% confidence interval {CI} 1.55 to 3.36; participants = 940; studies = 7; I 2 = 41%; low CoE); tamsulosin: 75/158 (47%) vs 40/139 (29%) (OR 2.40, 95% CI 1.29 to 4.45; participants = 297; studies = 3; I 2 = 30%; low CoE)] with rare adverse events. Similar rates were achieved with tamsulosin or alfuzosin [51/87 (59%) vs 45/84 (54%) (OR 1.28, 95% CI 0.68 to 2.41;

show abstract

“…6,7 The rate of acute urinary retention reported with OAB medications varies from~8% with onabotulinumtoxinA 12 to less than 1% with antimuscarinics and mirabegron 13 ; nevertheless, there is still a perception among physicians of an increased risk with antimuscarinics in male patients, which is often attributed to their mode of action. 14 In 12-week placebo-controlled trials, mirabegron and tolterodine extended release (ER) were associated with placebo-like changes in the PVR volume (−0.9 mL [mirabegron 50 mg], −1.6 mL [placebo], and +0.1 mL [tolterodine ER 4 mg]), and the incidence of urinary retention was negligible (0.1% [mirabegron 50 mg], 0.6% [tolterodine ER 4 mg], and 0.5% [placebo]). 13 In high-risk cohorts such as male OAB patients with obstructive symptoms, urodynamic parameters are unaffected and acute urinary retention remains low following monotherapy or combination treatment.…”

mentioning

confidence: 99%

Adding Mirabegron to Solifenacin to Treat Overactive Bladder Has Little Impact on Postvoid Residual Volume or Urinary Retention Risk

Drake

MacDiarmid²,

Аль-Шукри

et al. 2017

Urology

View full text Add to dashboard Cite

Acute Urinary Retention Rates in the General Male Population and in Adult Men With Lower Urinary Tract Symptoms Participating in Pharmacotherapy Trials: A Literature Review

Cited by 31 publications

References 50 publications

Management of Urinary Retention in Patients with Benign Prostatic Obstruction: A Systematic Review and Meta-analysis

Management of Urinary Retention in Patients with Benign Prostatic Obstruction: A Systematic Review and Meta-analysis

Management of urinary retention in patients with benign prostatic obstruction: A systematic review and meta-analysis

Adding Mirabegron to Solifenacin to Treat Overactive Bladder Has Little Impact on Postvoid Residual Volume or Urinary Retention Risk

Contact Info

Product

Resources

About